This segment focuses on the development and commercialization of genetic tests for the prediction and prevention of cardiovascular diseases (CVD). Key products include Cardio inCode and Lipid inCode, which utilize advanced genetic analysis and clinical algorithms to assess an individual's risk of developing CVD and familial hypercholesterolemia. Research & Development activities involve identifying novel genetic markers and refining risk prediction models. The segment leverages technologies such as next-generation sequencing and bioinformatics to analyze patient DNA samples. The therapeutic area covered is cardiology, with a focus on improving patient outcomes through early detection and personalized prevention strategies. Market positioning is centered on providing healthcare providers with actionable insights to manage patients at risk of CVD more effectively. Future opportunities include expanding the product portfolio to cover additional CVD-related conditions and increasing market penetration in the US and Europe. Collaborations with organizations like the Family Heart Foundation and the University of Texas Southwestern enhance the segment's research capabilities and market reach.

This segment is dedicated to the development of genetic tests for assessing the risk of ovarian cancer. The ALDO project, a partnership with the North Central London Cancer Alliance, exemplifies the company's commitment to early detection and prevention. Research and development efforts focus on identifying genetic markers associated with increased ovarian cancer risk and developing predictive models. The segment utilizes advanced genomic technologies and bioinformatics to analyze patient samples and provide personalized risk assessments. The therapeutic area is oncology, with a specific focus on women's health. The goal is to enable earlier diagnosis and intervention, ultimately improving patient outcomes. Market positioning involves offering innovative solutions for ovarian cancer risk assessment to healthcare providers and patients. Future opportunities include expanding the ALDO project and developing new genetic tests for other types of cancer. Regulatory and clinical aspects are carefully managed to ensure the accuracy and reliability of the tests.